• 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

000999 Share Price Performance

CN¥28.29
-5.90 (-17.26%)
CN¥28.29
-5.90 (-17.26%)
Price CN¥28.29

000999 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Undervalued with excellent balance sheet and pays a dividend.

1 Risk
3 Rewards

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Key Details

CN¥29.9b

Revenue

CN¥14.3b

Cost of Revenue

CN¥15.6b

Gross Profit

CN¥12.8b

Other Expenses

CN¥2.8b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
1.66
52.07%
9.25%
14.3%
View Full Analysis

About 000999

Founded
1999
Employees
20031
CEO
Wen Duo Wu
WebsiteView website
www.999.com.cn

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People’s Republic of China and internationally. The company offers health consumer products (CHC), including cold, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug products, such as anti-tumor, cardiovascular and cerebrovascular, digestive system, orthopedics, pediatrics, anti-infection, and other treatment areas; Chinese medicine health products; and vitamins, minerals, protein powder, collagen, probiotics, health foods, and formula granules. It also provides related health services. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. was founded in 1999 and is based in Shenzhen, China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a subsidiary of China Resources Pharmaceutical Group Limited.

Recent 000999 News & Updates

Recent updates

No updates